Boomerang academics: why we left academia for industry, but then came back
A move from one sector to another isn’t a one-way street. Researchers who have pivoted between the two explain why.
A move from one sector to another isn’t a one-way street. Researchers who have pivoted between the two explain why.
PURPOSE This review summarizes the published evidence on the clinical impact of using next-generation sequencing (NGS) tests to guide management of patients with cancer in…
Stay ahead in precision medicine with the 2nd Biennial Miami Precision Medicine conference. Join healthcare professionals for cutting-edge CME events, featuring expert insights, innovative strategies,…
Sarah Belcher, Susan Sereika, Jacqueline Dunbar-Jacob, Katherine Yeager, Margaret Rosenzweig, Mounzer Agha, Benyam Muluneh, Lindsay Sabik, Valire Copeland, Sarah McGregor, Catherine Bender University of Pittsburgh,…
Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. We aimed to evaluate wheth…
The OncoAlert Newsletter is now out for June 23-29, 2023
Dr. Hilary Robbins, an epidemiologist with the International Agency for Research on Cancer, and Dr. Brendon Stiles, chief of Thoracic Surgery and Surgical Oncol …
In a randomized trial of standard-risk adults, metformin decreased severe acute respiratory syndrome coronavirus 2 viral loads by an average of 0.56 log10
This case report illustrates the need for real-time integration of proteogenomic data from laser microdissected tumor specimens and dynamic biopsy testing
Tyrosine kinase inhibitors and immune checkpoint inhibitors (ICIs), each requiring testing for precision biomarkers, have recently been approved in the adjuvant setting. We assessed the…